[Pulmonary toxicity of antineoplastic agents--with special reference to current findings on pulmonary toxicity of bleomycin].
Pulmonary toxicity due to antitumor agents, chiefly bleomycin pulmonary toxicity including clinical feature, histopathology, pathophysiology, biochemical changes, common clinical settings (risk factors), and prevention was reviewed. Moreover, pulmonary toxicity from methotrexate, busulfan, cyclophosphamide, mitomycin C, 6-mercaptopurine, nitrosourea and procarbazine was reviewed.
D000818:Animals; D000970:Antineoplastic Agents / Q000633:toxicity; D001761:Bleomycin / Q000008:administration & dosage / Q000633:toxicity*; D002066:Busulfan / Q000633:toxicity; D003520:Cyclophosphamide / Q000633:toxicity; D006801:Humans; D008168:Lung / Q000187:drug effects* / Q000473:pathology / Q000503:physiopathology; D015122:Mercaptopurine / Q000633:toxicity; D008727:Methotrexate / Q000633:toxicity; D016685:Mitomycin; D008937:Mitomycins / Q000633:toxicity; D009607:Nitrosourea Compounds / Q000633:toxicity; D011183:Postoperative Complications; D011344:Procarbazine / Q000633:toxicity
D000970:Antineoplastic Agents; D008937:Mitomycins; D009607:Nitrosourea Compounds; D001761:Bleomycin; D011344:Procarbazine; D016685:Mitomycin; D003520:Cyclophosphamide; D015122:Mercaptopurine; D002066:Busulfan; D008727:Methotrexate